Biogen Exercises its Option with Ionis to Develop and Commercialize BIIB115/ION306 for the Treatment of SMA
Shots:
- Ionis received $60M one-time up front in Q4’21 & is eligible to receive post-licensing development, regulatory & commercial milestones along with royalties. Biogen is planning to advance BIIB115 in clinical trials to evaluate the safety, tolerability, PK & efficacy
- Following the option exercise, Biogen will be responsible for costs & expenses related to the development, manufacturing & commercialization of BIIB115. Additionally, companies also collaborated to develop novel therapies for neurological disorders
- BIIB115 is a preclinical investigational ASO & is designed to extend dosing intervals. Biogen has licensed the global rights to develop, manufacture & commercialize Spinraza
Ref: Biogen | Image: Biogen
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
